Evidence map›Paper›PMID 42799009›Full record

ArticleACS omega2026

Predicting Oncogenic Mutants of Epidermal Growth Factor Receptor in Lung Cancer by Molecular Dynamics Simulation with Machine Learning.

Victor O Anyanwu, Justin Spiriti, Chung F Wong

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Victor O AnyanwuDepartment of Chemistry and Biochemistry, University of Missouri-St Louis, 1 University Boulevard, St. Louis, Missouri 63121, United States.
Justin SpiritiDepartment of Chemistry and Biochemistry, University of Missouri-St Louis, 1 University Boulevard, St. Louis, Missouri 63121, United States.
Chung F WongDepartment of Chemistry and Biochemistry, University of Missouri-St Louis, 1 University Boulevard, St. Louis, Missouri 63121, United States.ORCID https://orcid.org/0000-0001-7782-4612

Funding

Computer-Aided Drug Design Targeting Protein PhosphorylationR15CA224033 · NCI · UNIVERSITY OF MISSOURI-ST. LOUIS · PI WONG, CHUNG F. · 2019 to 2025
$1.5M
NCI NIH HHS R15 CA224033
6 · The paper itself

Abstract

The epidermal growth factor receptor (EGFR) is a frequently mutated protein kinase found in patients suffering from non-small cell lung cancer (NSCLC). Although therapeutic drugs targeting EGFR are available, not all patients respond to these drugs, and it is not yet known whether some clinically detected mutations are actionable. Although the oncogenicity of some mutants is well established, many mutants found in patients are not yet classified or classified as Variants of Uncertain Significance. For newly discovered rare mutants, strong evidence supporting their classification into oncogenic or benign is often lacking. Under such situations, multiple pieces of evidence can still help classification, even if each individual piece of evidence is weaker. Computational predictions have been considered as supporting information by the Standard Operating Procedure (SOP) of the Clinical Genome Resource/Cancer Genomics Consortium/Variant Interpretation for Cancer Consortium (ClinGen/CGC/VICC). The SOP considers predictions from multiple computational programs as providing only one piece of supporting information to avoid double counting because these programs share common approaches. A computational approach that explicitly accounts for the conformational effects of mutations via molecular dynamics (MD) simulation could add another piece of complementary supporting information. We tested the hypothesis that features of structural dynamics observed from MD simulation could help distinguish oncogenic from benign mutants. To this end, we performed three independent MD simulations lasting 1 μs each for wild-type EGFR and 32 of its oncogenic or benign mutants. We found that random forest machine-learning models constructed using suitable structural features were able to distinguish oncogenic and benign mutations effectively. Although we did not supply features of structural motifs commonly used by scientists to distinguish active and inactive conformations, our machine-learning approach identified and utilized some features associated with these motifs for classifying EGFR mutants.

Identifiers

PMID42799009
PMCPMC13613388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.